iiinova — where your digital self keeps evolving

Reposted by Alice Perucca

IBEC | Institute for Bioengineering of Catalonia @ibecbarcelona.eu · 12/11/2025

🎙️ La nostra trobada de doctorands va posar el focus en una habilitat clau: la comunicació científica! Els estudiants van enregistrar entrevistes pel podcast Raticos de Ciencia amb el Dr. Julián Cerón-Madrigal. ✨ Escolta l’episodi aquí: Spotify/iVoox 👇 f.mtr.cool/fdrsxrlusl

131

Reposted by Alice Perucca

caixaresearch.bsky.social @caixaresearch.bsky.social · 12/11/2025

1/ 🔬🎨 Tanto en el arte como en la investigación del cáncer, mirar más allá de lo evidente puede cambiar por completo cómo vemos una obra y cómo entendemos una enfermedad. Te lo contamos en la #InstantáneasdelMes. 👇 bit.ly/4hVCkt5

101

Alice Perucca @aliperri.bsky.social · 10/02/2025

7/7 Friends 🎈 I am incredibly grateful to have worked alongside my wonderful co-first author, @oriolmb.bsky.social. This project has been a surprising journey, filled with challenges, triumphs, and lots of laughs. Cheers to the friendships made through science!

140

Alice Perucca @aliperri.bsky.social · 10/02/2025

6/7: Thanks! This work wouldn't have been possible without the contributions of co-authors: @oriolmb.bsky.social Andrea Gomez and all the authors: Alex Calon, Anna Labernadie @challopeau.bsky.social et al. Special thanks to @xaviertrepat.bsky.social for the opportunity to take part in this project.

120

Alice Perucca @aliperri.bsky.social · 10/02/2025

5/7: Impact. MIRO offers a valuable ex vivo platform that helps uncover mechanisms of immune exclusion potentially accelerating drug development, bridging the gap from lab to clinic 💊, ultimately improving patient outcomes. #TranslationalResearch

110

Alice Perucca @aliperri.bsky.social · 10/02/2025

4/7: MIRO enables high throughput testing of #immunotherapies, opening new possibilities for personalized cancer treatments. As a proof of concept, we restored anti-cancer immunity in resistant/immune-excluded HER2+ breast cancer with IL2 treatment. 💪 🎥 Immune cell migration upon treatment

130

Alice Perucca @aliperri.bsky.social · 10/02/2025

3/7: Why MIRO is unique? ✅ Immunocompetent: tracks #ImmuneCells movement & interactions ✅ Cells self-organize & build their own extra-cellular matrix ✅ Cost-effective, reproducible & user-friendly 🎥 cellular organization in MIRO #ECM #TumorEcosystem

121

Alice Perucca @aliperri.bsky.social · 10/02/2025

2/7: MIRO is an open fluidic device that models the tumour-stroma interface using patient-derived cells. This allows us to recreate aspects of the #TumorMicroenvironment and study immune cell interactions in the lab. 🔎🧫 #Microfluidics #OnChip

Left: 3D schematic representation of the cellular organisation in MIRO. Right: comparison between MIRO and patient sample cellular organization.

140

Alice Perucca @aliperri.bsky.social · 10/02/2025

1/7: New paper alert! Excited to share our co-first author paper on Micro Immune Response On-chip (MIRO) a model that recreates the tumour-stroma interface for immunotherapy testing! @oriolmb.bsky.social and I wrote this thread to break it down for you. 👇🧵 Read more: www.nature.com/articles/s41...

nature.com

Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing - Nature Communications

Modelling the tumour immune microenvironment in vitro is a valuable tool to test immunotherapy efficiency but capturing its complexity is challenging. Here authors present a fully humanised in vitro p...

12913

Reposted by Alice Perucca

Xavier Trepat @xaviertrepat.bsky.social · 07/02/2025

New paper from the lab🎈. Introducing Micro Immune Response On-chip (MIRO), a device that replicates tumors and their microenvironment to better understand responses to immunotherapies (cyan=immune cells, red=cancer, green=CAFs). www.nature.com/articles/s41... @ibecbarcelona.eu

814442

Alice Perucca @aliperri.bsky.social · 06/02/2025

Kicking off my Bluesky account with great news! Our work on MIRO, a device designed to study how cells respond to different immunotherapies, is now published. Have a look!

093